GRI Bio, Inc.
NASDAQTotal Valuation
GRI Bio, Inc. carries a market capitalization of 162,596.00, placing it among publicly traded companies globally. Its enterprise value stands at -9.91M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 162,596.00 |
| Enterprise Value | -9.91M |
Share Statistics
GRI Bio, Inc. currently has 1.58M shares outstanding.
| Shares Outstanding | 1.58M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.02 |
| P/TBV Ratio | 0.10 |
| P/FCF Ratio | -0.09 |
| P/OCF Ratio | -0.09 |
Financial Position
GRI Bio, Inc. maintains a current ratio of 14.21, meaning it holds 14.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 14.21 |
| Quick Ratio | 13.91 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -141.84 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
GRI Bio, Inc.'s stock has declined approximately -95.60253% over the past 52 weeks. The 50-day moving average sits at 2.14, while the 200-day moving average is 18.66.
| Beta (5Y) | N/A |
| 52-Week Price Change | -95.60253% |
| 50-Day Moving Average | 2.14 |
| 200-Day Moving Average | 18.66 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -10.92M, while operating income came in at -10.93M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -10.93M |
| Pretax Income | -10.91M |
| Net Income | -10.91M |
| EBITDA | -10.92M |
| EBIT | -10.93M |
| Earnings Per Share (EPS) | -23.15 |
Balance Sheet
GRI Bio, Inc. holds 11.05M in cash and equivalents against 58,000.00 in total debt, resulting in a net debt position of -11.05M. Total book value stands at -53.69M, with working capital of 10.49M providing operational flexibility.
| Cash & Cash Equivalents | 11.05M |
| Total Debt | 58,000.00 |
| Net Debt | -11.05M |
| Equity (Book Value) | -53.69M |
| Book Value Per Share | -113.97 |
| Working Capital | 10.49M |
Cash Flow
GRI Bio, Inc. produced -12.13M in operating cash flow over the past twelve months.
| Operating Cash Flow | -12.13M |
| Capital Expenditures | N/A |
| Free Cash Flow | -12.13M |
| FCF Per Share | -25.76 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -1,844.97 |
| FCF Yield | -1,124.78 |
Stock Splits
GRI Bio, Inc.'s most recent stock split took place on January 26, 2026 with a 28:1 split ratio.
| Last Split Date | 1/26/2026 |
| Split Ratio | 28:1 |
Scores
GRI Bio, Inc. posts an Altman Z-Score of -7.89, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.89 |